Trump Reshapes Obesity Drug Prices, Novo Tops Pfizer Again — This Week in Biotech #77

Subscribe to Biotech Blueprint for free at biotechblueprint.com.Pfizer’s courtroom gamble to block Novo Nordisk’s $10B Metsera takeover failed, and Novo immediately fired back with an even higher bid, leaving Pfizer two days to respond before the Nov. 13 vote. Meanwhile, Trump struck landmark pricing deals with Novo and Lilly to bring GLP-1 drugs like Ozempic and Mounjaro to Medicare at $245 a month. Moderna tightened its belt and beat expectations with $1 B in revenue, J&J scored an FDA win for Caplyta in depression, and Viking’s next-gen GLP-1 showed it can actually reverse metabolic syndrome.